E-LIB Suche - Ergebnisse für: Kipps, T. J.

1

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cel..:

Lee, H. ; Choi, M. ; Siddiqi, T....
Hematological Oncology. 41 (2023) S2 - p. 587-589 , 2023

Link: https://doi.org/10.1002/..

2

MURANO: Final 7 year follow up and retreatment analysis in ..:

Kater, A. P. ; Harrup, R. ; Kipps, T. J....
Hematological Oncology. 41 (2023) S2 - p. 239-242 , 2023

Link: https://doi.org/10.1002/..

3

P669: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-..:

Moreno, C. ; Wierda, W. G. ; Barr, P. M....
HemaSphere. 6 (2022) - p. 567-568 , 2022

Link: https://doi.org/10.1097/..

4

UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITU..:

Wu, J. Q. ; Seymour, J. F. ; Eichhorst, B....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

5

CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIX..:

Tam, C. S. L ; Allan, J. N ; Siddiqi, T...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

6

FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRON..:

Coutre, S. E. ; Barr, P. M. ; Owen, C....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

7

IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/..:

Wu, J. ; Bolen, C. ; Seymour, J.F....
Hematological Oncology. 37 (2019) S2 - p. 106-108 , 2019

Link: https://doi.org/10.1002/..

8

FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AN..:

Fischer, K. ; Porro Lurà, M. ; Al‐Sawaf, O....
Hematological Oncology. 37 (2019) S2 - p. 82-84 , 2019

Link: https://doi.org/10.1002/..

9

FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT O..:

Tedeschi, A. ; Burger, J. ; Barr, P.M....
Hematological Oncology. 37 (2019) S2 - p. 103-104 , 2019

Link: https://doi.org/10.1002/..

10

PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB‐INTOLERANT PATI..:

Rogers, K.A. ; Thompson, P.A. ; Allan, J.N....
Hematological Oncology. 37 (2019) S2 - p. 60-61 , 2019

Link: https://doi.org/10.1002/..

11

Leukemia-cell proliferation and disease progression in pati..:

Murphy, E J ; Neuberg, D S ; Rassenti, L Z...
Leukemia. 31 (2017) 6 - p. 1348-1354 , 2017

Link: https://doi.org/10.1038/..

12

Wnt5a induces ROR1 to complex with HS1 to enhance migration..:

Hasan, M K ; Yu, J ; Chen, L...
Leukemia. 31 (2017) 12 - p. 2615-2622 , 2017

Link: https://doi.org/10.1038/..

13

Extended follow-up and impact of high-risk prognostic facto..:

Brown, J R ; Hillmen, P ; O'Brien, S...
Leukemia. 32 (2017) 1 - p. 83-91 , 2017

Link: https://doi.org/10.1038/..

14

EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND RED..:

Tam, C.S. ; Byrd, J.C. ; O'Brien, S....
Hematological Oncology. 35 (2017) S2 - p. 233-234 , 2017

Link: https://doi.org/10.1002/..

15

LONG‐TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTI..:

Montillo, M. ; Byrd, J.C. ; Hillmen, P....
Hematological Oncology. 35 (2017) S2 - p. 235-236 , 2017

Link: https://doi.org/10.1002/..